Abstract
Background: The Glucagon Like Peptide 1 (GLP1) recep-tor agonists are a new class for treatment of both type 2 diabetes and obesity.
Aim of Study: To evaluate efficacy of GLP1 analogues in both weight reduction and glycemic control in obese Egyptians with and without diabetes.
Patients and Methods: This intervention study was con-ducted from August 2017 to August 2018. Total of 40 patients were divided into 3 groups: Obese group, obese group with diabetes & obese group with diabetes after failure to lose 10% of their initial weight after bariatric surgery. Clinical data were collected, anthropometric measures and laboratory investigation included fasting blood glucose and HbA1c in the beginning and every 3 months for a year were done.
Results: This study showed statistically significant body weight and BMI reduction in all groups, there was statistically significant reduction of fasting blood glucose, and HBA1c in the 2nd & 3rd group.
Conclusion: GLP1 analogues are effective in treatment of obese patients with and without diabetes.